Abstract
Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have gained attention as a means to shorten the course of treatment of drug-sensitive TB, improve treatment outcomes of drug-resistant TB and generally improve the efficacy and preserve or restore lung architecture of TB patients. It has been suggested that supplementing anti-TB therapy with host response modulators will augment standard TB treatment by overcoming antibiotic resistance in pathogenic strains of Mycobacterium tuberculosis (Mtb) and related species, thus aiding in killing non-replicating bacilli. Methods: The aim of this review is to examine pulmonary delivery strategies that can enhance the safety as well as efficacy of HDT against pulmonary TB. We reviewed literature in the public domain and revisited our own results on inhaled HDT to arrive at broad conclusions. Results: HDT can be viewed as a strategy to evoke one or more of the following macrophage responses: (i) soluble, intracellular factors such as free radicals and antimicrobial peptides; (ii) soluble extracellular signals like cytokines, chemokines, prostaglandins, lipids, etc.; (iii) organelles and assemblies such as phagolysosomes or the inflammasome; (iv) Autophagy, via mTOR/S6 Kinase; and (v) apoptosis via caspases, bcr/abl products, etc. All of these may be optimally addressed using drugs approved for other uses. Conclusion: Deployment of HDT in TB may be optimally achieved through macrophage-targeted inhaled delivery systems.
Keywords: Macrophage, inhalation, pulmonary drug delivery, nitric oxide, cytokines, apoptosis, autophagy.
Current Pharmaceutical Design
Title:Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Volume: 22 Issue: 17
Author(s): Madhur Sachan, Ashish Srivastava, Rajeev Ranjan, Anuradha Gupta, Sanketkumar Pandya and Amit Misra
Affiliation:
Keywords: Macrophage, inhalation, pulmonary drug delivery, nitric oxide, cytokines, apoptosis, autophagy.
Abstract: Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have gained attention as a means to shorten the course of treatment of drug-sensitive TB, improve treatment outcomes of drug-resistant TB and generally improve the efficacy and preserve or restore lung architecture of TB patients. It has been suggested that supplementing anti-TB therapy with host response modulators will augment standard TB treatment by overcoming antibiotic resistance in pathogenic strains of Mycobacterium tuberculosis (Mtb) and related species, thus aiding in killing non-replicating bacilli. Methods: The aim of this review is to examine pulmonary delivery strategies that can enhance the safety as well as efficacy of HDT against pulmonary TB. We reviewed literature in the public domain and revisited our own results on inhaled HDT to arrive at broad conclusions. Results: HDT can be viewed as a strategy to evoke one or more of the following macrophage responses: (i) soluble, intracellular factors such as free radicals and antimicrobial peptides; (ii) soluble extracellular signals like cytokines, chemokines, prostaglandins, lipids, etc.; (iii) organelles and assemblies such as phagolysosomes or the inflammasome; (iv) Autophagy, via mTOR/S6 Kinase; and (v) apoptosis via caspases, bcr/abl products, etc. All of these may be optimally addressed using drugs approved for other uses. Conclusion: Deployment of HDT in TB may be optimally achieved through macrophage-targeted inhaled delivery systems.
Export Options
About this article
Cite this article as:
Sachan Madhur, Srivastava Ashish, Ranjan Rajeev, Gupta Anuradha, Pandya Sanketkumar and Misra Amit, Opportunities and Challenges for Host-Directed Therapies in Tuberculosis, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128150636
DOI https://dx.doi.org/10.2174/1381612822666160128150636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Research Progress in Live Attenuated Brucella Vaccine Development
Current Pharmaceutical Biotechnology Glucolipotoxicity-induced Oxidative Stress is Related to Mitochondrial Dysfunction and Apoptosis of Pancreatic β-cell
Current Diabetes Reviews The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Biomarkers in the Diagnosis of Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Beyond Providing Drugs: the Mectizan® Donation Stimulates New Strategies in Service Delivery and in Strengthening Health Systems
Current Pharmaceutical Biotechnology A Clinical Scoring System as Useful as FNAC in the Diagnosis of Tuberculous Lymphadenitis in HIV Positive Patients
Current HIV Research Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Host-Pathogen Interactions Made Transparent with the Zebrafish Model
Current Drug Targets Predicting Protein-Ligand Binding Sites Based on an Improved Geometric Algorithm
Protein & Peptide Letters Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome<sup>#</sup>
Current Pharmaceutical Design Resistant Tuberculosis: the Latest Advancements of Second-line Antibiotic Inhalation Products
Current Pharmaceutical Design Vaccines and Vaccine Strategies Against HIV
Current Drug Targets Recent Progress in the Identification and Development of Anti-Malarial Agents Using Virtual Screening Based Approaches
Combinatorial Chemistry & High Throughput Screening Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Strategies for Antimicrobial Drug Delivery to Biofilm
Current Pharmaceutical Design A Review of the Treatment of Psoriasis with Infliximab
Reviews on Recent Clinical Trials Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry